Last 19 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q2 '19 | Q4 '18 | Q2 '18 | Q4 '17 | Q2 '17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -480.15 | 18.02 | — | — | 35.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 4.26 | 1.49 | 1.02 | 2.28 | 2.24 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 8.24 | 5.85 | 4.08 | 8.37 | 9.36 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | 174.48 | — | 80.46 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 94.89 | 66.32 | 27.29 | 54.27 | 17.84 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 211.23 | — | 68.53 | — | 16.53 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q2 '19 | Q4 '18 | Q2 '18 | Q4 '17 | Q2 '17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 53.1% | 51.6% | 52.8% | 48.6% | 64.9% | 65.6% | 79.5% | 41.1% | 33.0% | -64.8% | -402.4% | -384.1% | -228.9% | -536.7% | -342.1% | -339.5% | -226.0% | — | — | — |
| — | -21.3% | -33.6% | +18.2% | +96.8% | +201.2% | +119.8% | +110.7% | +114.4% | +87.9% | -17.6% | -13.1% | -1.3% | — | — | — | — | — | — | — | |
| Operating Margin | 2.2% | -2.9% | 1.6% | 2.7% | 11.5% | 7.3% | -5.5% | 14.2% | -7.1% | -264.0% | -1065.2% | -1085.9% | -808.2% | -1251.3% | -1443.5% | -890.5% | -8814.4% | — | — | — |
| — | -139.6% | +128.6% | -81.3% | +261.3% | +102.8% | +99.5% | +101.3% | +99.1% | +78.9% | +26.2% | -21.9% | +90.8% | — | — | — | — | — | — | — | |
| Net Margin | -0.9% | 8.0% | -1.2% | -0.6% | 6.4% | 6.2% | 6.9% | -6.5% | -24.4% | -294.8% | -1024.2% | -1117.3% | -737.3% | -1138.8% | -1049.3% | -570.5% | -4430.8% | — | — | — |
| — | +29.9% | -116.9% | +90.9% | +126.4% | +102.1% | +100.7% | +99.4% | +96.7% | +74.1% | +2.4% | -95.8% | +83.4% | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q2 '19 | Q4 '18 | Q2 '18 | Q4 '17 | Q2 '17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -1.8% | 8.4% | -1.1% | -0.6% | 7.9% | 4.2% | 17.4% | -18.4% | -35.8% | -131.8% | -191.6% | -51.2% | -40.1% | -29.6% | -30.9% | -21.6% | -17.8% | -11.1% | -17.2% | -48.6% |
| — | +98.1% | -106.6% | +96.9% | +122.0% | +103.2% | +109.1% | +64.2% | +10.6% | -345.8% | -520.4% | -137.4% | -125.5% | -166.8% | -79.2% | +55.6% | — | — | — | — | |
| ROA | -0.7% | 3.0% | -0.4% | -0.2% | 3.4% | 2.0% | 5.5% | -5.1% | -14.1% | -43.5% | -40.2% | -22.7% | -21.1% | -18.6% | -20.8% | -14.6% | -13.8% | -10.4% | -16.6% | -45.4% |
| — | +45.5% | -107.3% | +95.9% | +124.0% | +104.7% | +113.7% | +77.7% | +33.3% | -133.6% | -93.2% | -55.5% | -53.1% | -78.8% | -25.7% | +67.9% | — | — | — | — | |
| ROIC | 2.6% | -1.3% | 0.7% | 1.7% | 13.7% | 5.9% | -4254.0% | — | — | — | — | -1441.2% | -122.5% | -50.2% | -57.8% | -38.1% | -54.6% | -81.5% | -349.4% | — |
| — | -122.2% | +100.0% | — | — | — | — | — | — | — | — | -3682.6% | -124.4% | +38.3% | +83.5% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q2 '19 | Q4 '18 | Q2 '18 | Q4 '17 | Q2 '17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.12 | 1.19 | 1.12 | 0.99 | 1.02 | 0.05 | 0.12 | 0.17 | 0.13 | 0.02 | 1.18 | 0.04 | 0.03 | 0.06 | 0.03 | 0.04 | 0.03 | 0.01 | 0.01 | — |
| — | +2069.3% | +859.9% | +475.4% | +683.7% | +125.2% | -90.0% | +386.9% | +367.5% | -57.5% | +3769.2% | -15.3% | -14.5% | +596.8% | +333.9% | — | — | — | — | — | |
| Debt / EBITDA | 11.80 | 48.39 | 25.25 | 24.26 | 8.00 | 1.27 | — | 0.38 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +3705.4% | — | +6328.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.43 | 2.01 | 1.43 | 1.33 | 2.78 | 0.99 | 1.43 | 1.54 | 2.02 | 3.21 | 1.25 | 3.15 | 4.69 | 4.32 | 5.52 | 4.00 | 4.35 | 12.42 | 33.74 | 15.12 |
| — | +103.8% | -0.2% | -13.3% | +37.1% | -69.2% | +14.1% | -51.3% | -56.8% | -25.7% | -77.3% | -21.2% | +7.8% | -65.2% | -83.6% | -73.5% | — | — | — | — | |
| Quick Ratio | 1.27 | 1.85 | 1.27 | 1.22 | 2.66 | 0.87 | 1.32 | 1.45 | 1.93 | 3.07 | 1.16 | 3.11 | 4.66 | 4.28 | 5.47 | 3.86 | 4.27 | 12.42 | 33.74 | 15.12 |
| — | +113.3% | -4.0% | -16.2% | +38.2% | -71.7% | +13.6% | -53.5% | -58.7% | -28.2% | -78.8% | -19.3% | +9.1% | -65.6% | -83.8% | -74.5% | — | — | — | — | |
| Interest Coverage | 0.86 | -2.83 | 0.94 | -0.45 | 4.75 | 7.41 | 35.04 | -26.83 | -103.18 | -511.34 | -595.09 | -431.67 | -36.40 | -105.79 | -18.13 | -15.08 | -28.55 | -18.25 | -576.03 | -335.40 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 19 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TLX stock.
Telix Pharmaceuticals Limited's current P/E is -480.2x. The average P/E over the last 2 quarters is 26.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Telix Pharmaceuticals Limited's current operating margin is 2.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Telix Pharmaceuticals Limited's business trajectory between earnings reports.